

Cover Story
A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
In Brief


Drugs & Targets
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- CBER Director Vinay Prasad dared to “say no to drugs”
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?” - Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants











